Abstract
Systemic candidiasis is a serious global health concern with high mortality rates and growing drug resistance. Vaccination offers a promising solution. A unique approach involves using tiny lipid-coated particles called extracellular vesicles (EVs), which carry various fungal components. Previous studies found that Candida albicans EVs activate the immune response and may bridge the gap between innate and adaptive immunity. To understand this better, we investigated how these EVs activate immune cells. We demonstrated that specific components on EV surfaces, such as mannans and glucans, interact with receptors on immune cells, including Toll-like receptor 4 (TLR4) and dectin-1. Moreover, vaccinating with these EVs led to strong immune responses and full protection in mice infected with Candida . This work shows how harnessing fungal EVs might lead to effective vaccines against candidiasis.
Cite
CITATION STYLE
Honorato, L., Bonilla, J. J. A., Valdez, A. F., Frases, S., Araújo, G. R. de S., Sabino, A. L. R. do N., … Nimrichter, L. (2024). Toll-like receptor 4 (TLR4) is the major pattern recognition receptor triggering the protective effect of a Candida albicans extracellular vesicle-based vaccine prototype in murine systemic candidiasis. MSphere, 9(8). https://doi.org/10.1128/msphere.00467-24
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.